ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
CALM-AD

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators: Institute of Psychiatry, London
Medical Research Council
Alzheimer's Society
Information provided by: Institute of Psychiatry, London
ClinicalTrials.gov Identifier: NCT00142324
  Purpose

Primary Aim

To determine whether;

  • Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment

Secondary Aims

To determine whether;

  • Donepezil has a significant positive or negative impact upon quality of life compared with placebo
  • whether there is a significant difference between Donepezil and placebo with respect to cognitive performance
  • the cost effectiveness of the pharmacological treatment for agitation

Condition Intervention Phase
Alzheimer's Disease
Drug: Donepezil
Phase IV

Genetics Home Reference related topics:   Alzheimer disease   

MedlinePlus related topics:   Alzheimer's Disease    Dementia   

ChemIDplus related topics:   Donepezil    E 2020   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title:   A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention

Further study details as provided by Institute of Psychiatry, London:

Primary Outcome Measures:
  • Cohen Mansfield Agitation Inventory

Secondary Outcome Measures:
  • Neuropsychiatric Inventory
  • Standardized Mini-Mental State Examination
  • Severe Impairment Battery
  • Clinical Global Impression of Severity/Change

Estimated Enrollment:   190
Study Start Date:   November 2003
Estimated Study Completion Date:   December 2005

  Eligibility
Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria: a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score >39 age >39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate

-

Exclusion Criteria:known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance

-

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142324

Locations
United Kingdom
Queen Elizabeth Psychiatric Hospital    
      Birmingham, United Kingdom, B15 2QZ
Department of Psychiatry for the Elderly, Leicester General Hospital    
      Leicester, United Kingdom, LE5 4PW
Institute of Psychiatry, King's College, London    
      London, United Kingdom, SE5 8AF
Old Age Psychiatry, Wythenshawe Hospital, Manchester    
      Manchester, United Kingdom, M23 9LT
Department of Old Age Psychiatry, Victoria Hospital, Swindon    
      Swindon, United Kingdom, SN1 4HZ
Department of Psychiatry, Warneford Hospital, Oxford    
      Oxford, United Kingdom, OX3 7JX
MARC, Moorgreen Hospital, Southamptom    
      Southampton, United Kingdom, S030 3JB
Institute for Ageing and Health, Newcastle General Hospital, Newcastle    
      Newcastle upon Tyne, United Kingdom, NE4 6BE

Sponsors and Collaborators
Institute of Psychiatry, London
Medical Research Council
Alzheimer's Society

Investigators
Principal Investigator:     Robert Howard     Institute of Psychiatry, London    
Principal Investigator:     Peter Bentham     Queen Elizabeth Psychiatric Hospital, Birmingham    
Principal Investigator:     Richard Brown     Institute of Psychiatry, London    
Principal Investigator:     Roger Bullock     Kingshill Research Centre, Victoria Hospital, Swindon    
Principal Investigator:     Alistair Burns     Wythenshawe Hospital, Manchester    
Principal Investigator:     Clive Holmes     Moorgreen Hospital, Southampton    
Principal Investigator:     Robin Jacoby     Warneford Hospital, Oxford    
Principal Investigator:     James Lindesay     Leicester General Hospital, Leicester    
Principal Investigator:     John O'Brien     Newcastle General Hospital, Newcastle    
  More Information


Publications indexed to this study:

Study ID Numbers:   ISRCTN62185868
First Received:   September 1, 2005
Last Updated:   December 13, 2005
ClinicalTrials.gov Identifier:   NCT00142324
Health Authority:   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Institute of Psychiatry, London:
Dementia  

Study placed in the following topic categories:
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Donepezil
Alzheimer Disease
Central Nervous System Diseases
Psychomotor Agitation
Neurodegenerative Diseases
Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:
Nervous System Diseases
Tauopathies

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers